Bernardete Pessoa1,2,3, João Heitor4,5,6, Constança Coelho5,7, Magdalena Leander8,5, Pedro Menéres4,5,6, João Figueira5,9,10,11, Angelina Meireles4,5,6, Melo Beirão4,8,5. 1. Departamento de Oftalmologia, Hospital de Santo António, Centro Hospitalar Universitário Do Porto, Largo Prof. Abel Salazar-Edifício Neoclássico, 4099-001, Porto, Portugal. bbtpessoa@gmail.com. 2. Unit for Multidisciplinary Investigations in Biomedicine (UMIB/ICBAS/UP), Porto, Portugal. bbtpessoa@gmail.com. 3. Laboratory of Cytometry, Unit for Diagnosis in Hematology, Clinical Hematology Department, Centro Hospitalar Universitário Do Porto, Porto, Portugal. bbtpessoa@gmail.com. 4. Departamento de Oftalmologia, Hospital de Santo António, Centro Hospitalar Universitário Do Porto, Largo Prof. Abel Salazar-Edifício Neoclássico, 4099-001, Porto, Portugal. 5. Laboratory of Cytometry, Unit for Diagnosis in Hematology, Clinical Hematology Department, Centro Hospitalar Universitário Do Porto, Porto, Portugal. 6. Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade Do Porto, Porto, Portugal. 7. Instituto de Saúde Ambiental, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal. 8. Unit for Multidisciplinary Investigations in Biomedicine (UMIB/ICBAS/UP), Porto, Portugal. 9. Centro Hospitalar E Universitário de Coimbra, Coimbra, Portugal. 10. Faculty of Medicine, University of Coimbra, Coimbra, Portugal. 11. Association for Innovation and Biomedical Research On Light and Image, Coimbra, Portugal.
Abstract
PURPOSE: Diabetic retinopathy (DR) is a microvascular inflammatory and neurodegenerative disease. The purpose of this study was to analyze the relationship between DR severity and the levels of potential biomarkers in the serum and/or vitreous. METHODS: A prospective, consecutive, controlled, observational study was performed between June 2018 and January 2020. Blood and vitreous samples were collected on the day of vitrectomy in patients without diabetes and in patients with diabetes with epiretinal membrane, macular edema, and indication for vitrectomy. RESULTS: Transthyretin (TTR) was the only blood biomarker with levels statistically higher in patients with diabetes (p = 0.037). However, no correlation with DR severity was observed. Erythropoietin (EPO) was the only blood biomarker whose levels were associated with DR severity (p = 0.036). In vitreous samples, levels of EPO (p = 0.011), interleukin (IL)-6 (p < 0.001), IL-8 (p < 0.001), IL-17 (p = 0.022), monokine induced by interferon-γ (MIG) (p < 0.001), and interferon gamma-induced protein 10 (IP-10) (p = 0.005) were significantly higher in patients with diabetes. Additionally, in vitreous, IL-6, IL-8, MIG, and IPL-10 levels were also higher in more severe DR cases (p < 0.05). CONCLUSIONS: Among the studied biomarkers, vitreous IL-6, IL-8, MIG, and IP-10 were the ones whose levels had the strongest coherent relationship with DR severity prediction and, thus, have the best potential post-vitrectomy prognostic value.
PURPOSE: Diabetic retinopathy (DR) is a microvascular inflammatory and neurodegenerative disease. The purpose of this study was to analyze the relationship between DR severity and the levels of potential biomarkers in the serum and/or vitreous. METHODS: A prospective, consecutive, controlled, observational study was performed between June 2018 and January 2020. Blood and vitreous samples were collected on the day of vitrectomy in patients without diabetes and in patients with diabetes with epiretinal membrane, macular edema, and indication for vitrectomy. RESULTS: Transthyretin (TTR) was the only blood biomarker with levels statistically higher in patients with diabetes (p = 0.037). However, no correlation with DR severity was observed. Erythropoietin (EPO) was the only blood biomarker whose levels were associated with DR severity (p = 0.036). In vitreous samples, levels of EPO (p = 0.011), interleukin (IL)-6 (p < 0.001), IL-8 (p < 0.001), IL-17 (p = 0.022), monokine induced by interferon-γ (MIG) (p < 0.001), and interferon gamma-induced protein 10 (IP-10) (p = 0.005) were significantly higher in patients with diabetes. Additionally, in vitreous, IL-6, IL-8, MIG, and IPL-10 levels were also higher in more severe DR cases (p < 0.05). CONCLUSIONS: Among the studied biomarkers, vitreous IL-6, IL-8, MIG, and IP-10 were the ones whose levels had the strongest coherent relationship with DR severity prediction and, thus, have the best potential post-vitrectomy prognostic value.
Authors: Cristina Hernández; Alex Fonollosa; Marta García-Ramírez; Mónica Higuera; Roberto Catalán; Adela Miralles; José García-Arumí; Rafael Simó Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: Pouya Saeedi; Inga Petersohn; Paraskevi Salpea; Belma Malanda; Suvi Karuranga; Nigel Unwin; Stephen Colagiuri; Leonor Guariguata; Ayesha A Motala; Katherine Ogurtsova; Jonathan E Shaw; Dominic Bright; Rhys Williams Journal: Diabetes Res Clin Pract Date: 2019-09-10 Impact factor: 5.602
Authors: Elliott H Sohn; Hille W van Dijk; Chunhua Jiao; Pauline H B Kok; Woojin Jeong; Nazli Demirkaya; Allison Garmager; Ferdinand Wit; Murat Kucukevcilioglu; Mirjam E J van Velthoven; J Hans DeVries; Robert F Mullins; Markus H Kuehn; Reinier Otto Schlingemann; Milan Sonka; Frank D Verbraak; Michael David Abràmoff Journal: Proc Natl Acad Sci U S A Date: 2016-04-25 Impact factor: 11.205
Authors: Joanne W Y Yau; Sophie L Rogers; Ryo Kawasaki; Ecosse L Lamoureux; Jonathan W Kowalski; Toke Bek; Shih-Jen Chen; Jacqueline M Dekker; Astrid Fletcher; Jakob Grauslund; Steven Haffner; Richard F Hamman; M Kamran Ikram; Takamasa Kayama; Barbara E K Klein; Ronald Klein; Sannapaneni Krishnaiah; Korapat Mayurasakorn; Joseph P O'Hare; Trevor J Orchard; Massimo Porta; Mohan Rema; Monique S Roy; Tarun Sharma; Jonathan Shaw; Hugh Taylor; James M Tielsch; Rohit Varma; Jie Jin Wang; Ningli Wang; Sheila West; Liang Xu; Miho Yasuda; Xinzhi Zhang; Paul Mitchell; Tien Y Wong Journal: Diabetes Care Date: 2012-02-01 Impact factor: 19.112
Authors: Joseph D Boss; Pawan Kumar Singh; Hemang K Pandya; Joaquin Tosi; Chaesik Kim; Asheesh Tewari; Mark S Juzych; Gary W Abrams; Ashok Kumar Journal: Invest Ophthalmol Vis Sci Date: 2017-10-01 Impact factor: 4.799